CMC Risk Diagnostic
A focused assessment of your CMC position that identifies gaps in analytical, manufacturing, and control documentation and ranks the risks most likely to affect upcoming milestones.
Learn More about CMC Risk DiagnosticCMC strategy grounded in science and regulatory experience.
Regulatory CMC guidance for small-molecule, peptide, and oligonucleotide therapeutics, from pre-IND planning through clinical development.
Scientific Development
Connect analytical, formulation, and manufacturing considerations with phase-appropriate regulatory CMC strategy.
Regulatory Review
Identify submission gaps, anticipate review questions, and prioritize issues that could affect development milestones.
Strategic CMC Guidance
Align technical partners, development priorities, and regulatory deliverables through focused CMC leadership.
Three engagements, matched to your development stage.
From a focused CMC risk assessment to IND readiness and ongoing CMC leadership.
IND-Ready CMC System™
Develop a phase-appropriate CMC strategy and submission package aligned with regulatory expectations and your program’s development stage.
Learn More about IND-Ready CMC System™
CMC Leadership Retainer
Ongoing regulatory CMC leadership and strategic advice as development priorities, manufacturing partners, and regulatory requirements evolve.
Learn More about CMC Leadership RetainerWhy Nexus
Specialized expertise. Direct collaboration.
Nexus works with emerging biotech and lean pharmaceutical teams to identify CMC risk, coordinate CDMO and laboratory partners, and prepare regulatory documentation appropriate to each stage of development.
Modality focus
Regulatory CMC experience across small-molecule, peptide, and oligonucleotide programs and their distinct analytical and manufacturing considerations.
Review-informed perspective
Experience spanning regulatory review and pharmaceutical development shapes how we anticipate agency questions and weigh CMC risk.
Direct senior engagement
Engagements are led directly by senior CMC expertise and scoped to the milestone in front of you.
Latest insights from Nexus.
LinkedIn Post
LinkedIn post: Analytical methods do not need to be final on Day…
Analytical methods do not need to be final on Day 1. But they do need to be fit for the decisions they are supporting. For emerging biotech sponsors preparing INDs, this is an important distinction. Early clinical-stage CMC packages often rely on phase-appropriate analytical methods, but “phase-appropriate” should not mean loosely defined or poorly justified. ICH Q2(R2) keeps analytical validation focused on core expectations such as specificity, accuracy, precision, detection and quantitation limits, linearity, and range. For small molecules, synthetic peptides, and synthetic oligonucleotides, those expectations connect directly to impurity control, release testing, stability strategy, and overall control strategy. The practical question for sponsors is: Can your current method support the regulatory decision you are asking FDA to make? If the answer is unclear, the issue may not be the method itself. It may be the rationale, validation strategy, or lifecycle plan around it. At Nexus CMC Advisors, we help sponsors translate CMC expectations into practical, phase-appropriate regulatory strategy.
LinkedIn Post
LinkedIn post: The goal of early CMC strategy is not to have…
The goal of early CMC strategy is not to have every answer on day one. It is to make informed decisions early enough to avoid preventable rework, preserve flexibility, and build a more credible path toward the IND. That starts with asking better questions: • What is most likely to create avoidable rework? • What needs to be phase-appropriate now? • What will make the future IND more credible? The First IND CMC Playbook is designed to help biotech founders and leaders navigate those decisions with more clarity and confidence. Explore the playbook: https://a.co/d/0bl0NMae #Biotech #CMCStrategy #INDReady #DrugDevelopment #BiotechFounders
LinkedIn Post
LinkedIn post: When a sponsor came to us with a tight IND…
When a sponsor came to us with a tight IND clock and Module 3 sections drafted end-to-end by AI, the fix wasn’t more automation — it was regulatory judgment. Their Phase 1/2 small-molecule program had gone through recent manufacturing and controls changes between clinical batches, and their AI-generated drafts had over-shared information not required for early phase, misplaced content across sections, and blurred what belonged in the IND vs. what should stay with the CDMO. In six weeks, we right-sized every section to the clinical phase, partnered with them and their CDMO to pull the correct source documents, and rewrote language and regulatory commitments where they mattered — clearing the path to an on-time FDA submission. AI can accelerate a first draft. It can’t decide what an FDA reviewer needs to see at Phase 1/2. #CMC #RegulatoryAffairs #INDSubmission #EmergingBiotech #NexusCMCAdvisors